Medical Pharma, Inc. (OTCQB:TRGM), reported today on the completion
of an independent sales agreement with Pacific Medical, Inc., a
distributor of durable medical equipment in the United States who
specializes in orthopedic, rehabilitation, surgery and sports medicine.
The non-exclusive agreement will allow Targeted Medical Pharma to expand medical
food sales and education programs to licensed healthcare
professionals in Northern California and Northern Nevada for an initial
period of one year. The programs will focus on educating prescribers who
are currently treating patients with sleep, pain,
disorders about safe, effective, non-narcotic medical food treatment
"Pacific Medical is another important new business partner of Targeted
Medical Pharma, we are very pleased with the sales contract and believe
that Pacific Medical's stellar reputation for delivering quality
products and education programs will help healthcare providers
understand the importance of utilizing our medical food products as a
first line therapy for mitigating pain and inflammation without the
risks associated with narcotic pain medications," said William Shell,
M.D. CEO and Chief Science Officer of Targeted Medical Pharma, Inc. "We
believe that Pacific Medical will help enhance the quality of our sales
and education program and increase our market penetration with
orthopedic and sports medicine specialists."
About Targeted Medical Pharma, Inc.
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company also develops a line of dietary
supplements designed to support health and wellness. The company
manufactures 10 proprietary medical foods, and recently launched its
first dietary supplement, Clearwayz™.
The products are sold directly to physicians and pharmacies in the
U.S. The company also is developing nutrient-based systems for oral
stimulation of progenitor stem cells that differentiate into neurons,
red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to
Targeted Medical Pharma's business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions, identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could differ
materially. Targeted Medical Pharma expressly disclaim any obligation or
undertaking to update or revise any forward-looking statement contained
herein to reflect any change in the company's expectations with regard
thereto or any change in events, conditions or circumstances upon which
any statement is based.
[ Back To NFVZone's Homepage ]